Gout drug tapering trial: less medicine, same relief?

NCT ID NCT06622603

Recruiting now Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Apr 30, 2026 · Last updated May 16, 2026 · Updated 3 times

Summary

This study looks at whether people with gout who have kept their uric acid levels low for at least 5 years can safely take a lower dose or even stop their medication without symptoms coming back. About 59 adults will be split into three groups: one that reduces their febuxostat dose, one that stops it for 6 months then restarts a low dose, and one that stays on their current treatment. Researchers will track uric acid levels and any flare-ups over a year to find the best long-term management strategy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Seoul National University Bundang Hospital
RECRUITING

Seongnam-si, Gyeonggi-do, 463-707, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GOUT URIC ACID